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CASE REPORT 
Joints, bones and congenital heart disease…  
A forgotten association? 
Rachel Xuereb, Maryanne Caruana, Michela Frendo
A 20 year old Caucasian male, with a history of uncorrected cyanotic 
congenital heart disease, presented with a one year history of bone 
pains in his thighs, legs and forearms. The diagnosis of hypertrophic 
osteoarthropathy (HOA) was picked up on bone scintigraphy. HOA is 
usually associated with lung disease and the link with congenital 
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INTRODUCTION 
Gout, as a result of increased red cell turnover 
and hyperuricaemia, is the most commonly 
recognised cause of joint disease in patients 
with cyanotic congenital heart disease. We 
describe a case of hypertrophic 
osteoarthropathy (HOA), a far less common 
cause of bone disease in patients with 
congenital heart disease. It is now becoming 
increasingly rare to see HOA in these patients, 
as surgical correction of most congenital heart 
defects is now successfully being performed 
earlier on in life. 
CASE PRESENTATION  
A 20 year old male was referred to the 
Rheumatology Department complaining of 
bone pains in the upper thighs, legs and 
forearms over the past year. The pain was 
present throughout day and was not affected 
by activity. He denied nocturnal pain, joint 
swelling, systemic upset, rashes, fever, mouth 
ulcers or sicca symptoms.  
 
Figure 1 Whole body bone scan 
 Increased tracer uptake along the diaphyseal and metaphyseal surfaces of the femoral 
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He was born with complex congenital heart 
disease, in the form of dextrocardia, double 
outlet right ventricle and subvalvular 
pulmonary stenosis. At the age of one year, he 
underwent a palliative Blalock-Taussig shunt in 
view of worsening cyanosis but over time 
developed pulmonary vascular disease and 
subsequent Eisenmenger syndrome. He had 
been established on advanced pulmonary 
vasodilators for several years. 
On examination, the patient had an oxygen 
saturation of 62% on room air. He had clubbing 
of the digits and central cyanosis. There was no 
evidence of synovitis or joint deformities, but 
thickening of the distal part of both tibiae was 
noted. There was no overlying erythema or 
tenderness. Blood investigations were normal, 
apart from a high haemoglobin of 20.2 g/dL 
(14.1 - 17.2 g/dL) with a high haematocrit level 
of 59.3% (40.4 - 50.4%), slightly elevated uric 
acid of 507 umol/l (202 - 416 umol/l) and high 
alkaline phosphatase of 225 U/l (40 - 104 U/l). 
Autoimmune screen including antinuclear 
antibody, rheumatoid factor and anti-cyclic 
citrullinated peptide antibody was negative. 
Plain X-rays of hands and lower legs showed no 
abnormalities. Whole body bone scan, Figure 1, 
showed increased tracer uptake along the 
diaphyseal and metaphyseal surfaces of both 
femoral bones and tibiae and to a lesser 
degree the radius and ulna bilaterally. These 
findings are in keeping with HOA. The patient 
was treated with paracetamol and non-
steroidal agents. He is being followed up 
regularly at rheumatology out-patient clinic 




HOA is characterised by triad of severe 
disabling arthralgia and arthritis, digital 
clubbing and periostosis of tubular bones with 
or without synovial effusion. HOA was first 
described by Eugen von Bamberger and Pierre 
Marie in 1890.1 In rare cases it is inherited as an 
autosomal dominant condition, known as 
pachydermoperiostosis. In 95-97% of cases, it 
is secondary to pulmonary or extrapulmonary 
diseases, Table 1. The majority of these cases 
are of pulmonary origin, when it is known as 
hypertrophic pulmonary osteoarthropathy 
(HPOA). 90% of these are associated with 
malignancy. Non-small cell lung cancer 
(NSCLC), specifically adenocarcinoma, is the 
most common cause (0.7-17%). Although 
lower in absolute incidence, a higher 
percentage of pleural tumours result in HPOA, 
22% of solitary fibrous tumours of pleura as 
compared to 5% of NSCLC.1  
Three pathways for the mechanism of 
development of HOA have been proposed:  
1. Vascular pathway due to secretion of 
vasoactive agents by the tumour or due 
to arteriovenous shunting within the 
pulmonary circulation, 
2. Neurogenic pathway triggered by vagal 
innervation, resulting in vasodilatation 
and increased blood circulation to the 
extremities, 
3. Hypoxaemia driven surge of circulating 
growth factors e.g. platelet-derived 
growth factor, vascular endothelial 
growth factor (VEGF) and prostaglandin 
E2.   
The latter is the proposed mechanism in 
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Table 1 Causes of generalised HOA 
Pulmonary  Cardiac Gastrointestina
l 







Polyposis  Cirrhosis Thymoma 
Mesothelioma Atrial myxoma Malignancy Biliary atresia POEMS 
syndrome 
























    
Solitary fibrous 
tumours of the pleura 
    
POEMS: polyneuropathy, organomegaly, endocrinopathy, myeloma protein and skin changes. 
 
Patients with HOA share common features: 
pleomorphic platelets, giant 
macrothrombocytes with aberrant volume 
distribution curves, glomerular enlargement 
with entrapped megakaryocytic nuclei and 
high circulating levels of von Willebrand factor 
antigen.2 All these lead to the activation of 
platelets and endothelial cells, with the 
subsequent release of growth factors. 
Electron microscopy shows structural damage 
to vessel integrity with prominent Golgi 
complexes, activated endothelia, duplicated 
capillary basement membranes and 
perivascular infiltrate. At the level of joints the 
pathologic changes are dominated by arterial 
wall thickening.3 
There are no specific serological markers of 
HOA and as a result, the diagnosis of HOA is 
often delayed. Bone formation markers such 
as alkaline phosphatase, osteocalcin or amino-
terminal propeptide of type 1 pro-collagen 
may be increased. 
Imaging is the mainstay of diagnosis. X-rays 
typically show symmetrical periostosis of the 
shafts of tubular bones in the absence of 
cortical destruction or fracture. The tibia, 
fibula, radius and ulna are most commonly 
affected sites. Magnetic resonance imaging 
shows a low to intermediate signal intensity on 
T1 and T2 weighted images, highlighting 
periosteal elevation and reaction.4 There are 
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cases where HOA was diagnosed on positron 
emission tomography by increased 
fluorodeoxyglucose (FDG) uptake, however 
there is the risk of an erroneous diagnosis of 
metastatic disease.5 Bone scintigraphy with 
technetium 99m (99mTc) methylene 
diphosphonate (MDP) is the gold standard and 
is the most sensitive test. 
The differential diagnosis of HOA includes 
thyroid acropachy, hypervitaminosis A and a 
rare autosomal dominant disease known as 
Camurati Engelmann disease. Voriconazole 
has been reported to cause periostitis that 
mimics HOA.  
Management of HOA includes treatment of 
the underlying cause and appropriate 
analgesia. Other treatment options described 
include: unilateral vagotomy, in cases of 
inoperable primary lung malignancies. The 
procedure was first carried out in the 1950s 
and was revisited in 2006, however not many 
cases have been reported in the literature.6  
Adrenergic blockade with propranolol or 
phenoxybenzamine was trialled once in 1976.7 
This option has not been used favourably. 
NSAIDs, currently the most widely used 
treatment option, work by blocking the 
prostaglandin pathway. In fact, opioids are less 
effective. Octeotride, a VEGF inhibitor, has 
been shown to limit endothelial proliferation 
and is highly effective in pain relief.8 There are 
several case reports regarding the 
symptomatic and therapeutic effects of 
bisphosphonates, also VEGF inhibitors.9 
Therapeutic trials are currently being carried 
out with bevacizumab, a VEGF inhibitor and 
erlotinib, an epidermal growth factor receptor 
tyrosine kinase inhibitor, which could show 
promising results.10 
CONCLUSION  
Bone pains in patients suffering from 
malignancy, chronic lung disease, liver disease 
or cyanotic heart disease should raise the 
suspicion for HOA. Likewise, a new diagnosis of 
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